Literature DB >> 16198147

Early liaisons between cells of the innate immune system in inflamed peripheral tissues.

Alessandro Moretta1, Emanuela Marcenaro, Simona Sivori, Mariella Della Chiesa, Massimo Vitale, Lorenzo Moretta.   

Abstract

The crosstalk between natural killer (NK) cells and myeloid dendritic cells (DCs) results in NK-cell activation and DC maturation. Activated NK cells acquire the ability to kill DCs that have failed to undergo complete maturation ('DC editing'). Recent studies have revealed that this crosstalk can be promoted by pathogen-derived products that activate different innate immune cell types directly and simultaneously through their Toll-like receptors (TLRs). These cells include NK cells and DCs, as well as plasmacytoid DCs (PDCs) and mast cells. This crosstalk can have a great impact on the quality and strength of the subsequent adaptive immune response. Thus, NK cells have an important role in the defense against pathogens, acting as regulatory cells as well as effector cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198147     DOI: 10.1016/j.it.2005.09.008

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  54 in total

1.  The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes.

Authors:  Francesca Bellora; Roberta Castriconi; Alessandra Dondero; Giorgio Reggiardo; Lorenzo Moretta; Alberto Mantovani; Alessandro Moretta; Cristina Bottino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-30       Impact factor: 11.205

2.  Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation.

Authors:  Andrea De Maria; Federica Bozzano; Claudia Cantoni; Lorenzo Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha.

Authors:  Fabienne Brilot; Till Strowig; Susanne M Roberts; Frida Arrey; Christian Münz
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

Review 4.  Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response.

Authors:  A Reschner; P Hubert; P Delvenne; J Boniver; N Jacobs
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

5.  In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma.

Authors:  Abner A Murray; Chao Wang; Steven Fiering; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2018-05-25       Impact factor: 4.939

6.  Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells.

Authors:  Andrea Sobo-Vujanovic; Stephan Munich; Nikola L Vujanovic
Journal:  Cell Immunol       Date:  2014-04-08       Impact factor: 4.868

Review 7.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

8.  Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses.

Authors:  Roberto Biassoni; Elisabetta Ugolotti; Andrea De Maria
Journal:  Self Nonself       Date:  2010-03-06

9.  Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity.

Authors:  Mirna Balsamo; Francesca Scordamaglia; Gabriella Pietra; Claudia Manzini; Claudia Cantoni; Monica Boitano; Paola Queirolo; William Vermi; Fabio Facchetti; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari; Massimo Vitale
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-23       Impact factor: 11.205

10.  Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.

Authors:  K Ishiyama; T Kitawaki; N Sugimoto; T Sozu; N Anzai; M Okada; M Nohgawa; K Hatanaka; N Arima; T Ishikawa; S Tabata; T Onaka; S Oka; Y Nakabo; R Amakawa; M Matsui; T Moriguchi; A Takaori-Kondo; N Kadowaki
Journal:  Leukemia       Date:  2016-06-14       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.